Skip to main content

Alloy acquires deepCDR and will expand Basel site

| News

Alloy acquires deepCDR and will expand Basel site

10.12.2021

Alloy Therapeutics, a biotechnology firm from Boston in the USA, has acquired the Basel-based startup deepCDR Biologics. Alloy labs and deepCDR facilities in Basel are to be expanded into a permanent research center.

Alloy Therapeutics has acquired the startup deepCDR Biologics and opted for Basel as the location for a permanent research facility. According to a press release issued by the biotechnology firm from the US city of Boston, Alloy is acquiring the Basel-based startup with the aim of using its new antibody discovery and development method. Alloy already operates labs in Basel, but following the takeover of deepCDR will seek to transfer its facilities to a permanent Alloy research center.

Additional computer scientists and developers are to be hired at the Basel site as the Alloy network grows. Basel is set to become the location for bioinformatics and machine learning in the discovery of antibodies. The deepCDR team and technology will strengthen Alloy’s antibody discovery platform and system services from more than 100 global partners, the press release states.

DeepCDR Biologics is a spin-off from the Swiss Federal Institute of Technology in Zurich (ETH). Only last year, it successfully patented its new discovery and development method for antibodies. This should accelerate the development of next-generation antibody drugs. The new method makes use of the deep learning capabilities and is also faster and significantly more cost-effective than previous methods.

Errik Anderson, CEO and founder of Alloy Therapeutics, expects that his firm’s network partners will use the deepCDR method to open up research opportunities “that otherwise would have been cost prohibitive or inaccessible”. These types of technological improvements will serve to enhance the output of Alloy in terms of drug research activities, Anderson adds.

“The data sets and infrastructure within Alloy unlock powerful new opportunities for the deepCDR technology and team that will in turn enable us to help drug discovery teams more effectively and efficiently find the best antibody candidates”, explains Sai Reddy, founder of deepCDR, in discussing the cooperation in the press release.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.